NeuroAiD(TM)II holds promise as a safe add-on therapy to standard Alzheimer Disease symptomatic treatments and may have a disease modifying effect by delaying disease progression
SINGAPORE, Jan. 13, 2022 /PRNewswire/ — Moleac is pleased to announce the release of the ATHENE study results, published in
Read More